Losartan: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #8 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Angiotensin receptor blockers]] | |||
[[Category:Antihypertensives]] | |||
Latest revision as of 10:43, 23 May 2026
Losartan
Cozaar
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
50 mg PO daily (25 mg in volume depletion or hepatic impairment)
Preparations
25 mg, 50 mg, 100 mg tablets
US FDA Max
100 mg/d
Pharmacology
Routes
Oral
Onset
BP effect 1-2 weeks; antihypertensive peak 3-6 weeks
Duration
24 hours
Half-life
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174[1]
Bioavailability
~33% (extensive first-pass via CYP2C9 and CYP3A4)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Losartan is a selective AT1 angiotensin-II receptor antagonist; blocking AT1 produces vasodilation, decreased aldosterone, and reduced sodium retention without the bradykinin accumulation that drives ACE-inhibitor cough.0 Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Cozaar (losartan potassium), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s059lbl.pdf